A phase I single-agent study of twice-weekly consecutive-day dosing of the proteasome inhibitor carfilzomib in patients with relapsed or refractory multiple myeloma or lymphoma (Q33402144)
Jump to navigation
Jump to search
scientific article
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | A phase I single-agent study of twice-weekly consecutive-day dosing of the proteasome inhibitor carfilzomib in patients with relapsed or refractory multiple myeloma or lymphoma |
scientific article |
Statements
1 reference
A phase I single-agent study of twice-weekly consecutive-day dosing of the proteasome inhibitor carfilzomib in patients with relapsed or refractory multiple myeloma or lymphoma (English)
1 reference
Suzanne Trudel
1 reference
Owen A O'Connor
1 reference
Melissa Alsina
1 reference
Richard R Furman
1 reference
Peter J Rosen
1 reference
Raymond L Comenzo
1 reference
Alvin Wong
1 reference
Lori A Kunkel
1 reference
Christopher J Molineaux
1 reference
Andre Goy
1 reference
3 July 2012
1 reference
1 reference
18
1 reference
17
1 reference
4830-4840
1 reference
Identifiers
1 reference
1 reference